We aimed to determine whether the administration of statins to type  diabetics without preexisting CHD reduced the incidence of CHD and their eff ects on cholesterol and CRP levels. All the participants were carefully interviewed, clinically examined, and laboratory tested to exclude conditions likely to provoke an infl ammatory response that was an exclusion criterion. Exclusion criteria: Serious heart, liver or kidney problems, history of renal transplant, recent history of drug or alcohol abuse, HbAc>, blood pressure >/mmHg, BMI > kg/m  , triglycerides >,mmol/dm  .  obese diabetics (mean age , years and BMI=, kg/m  , diabetes duration more than  years) without pre-existing CHD, were included in the analysis and were randomized to simvastatin ( female and  male used  mg simvastatin daily) or placebo ( female and  male) group. After six months, simvastatin signifi cantly lowered CRP levels by , (p<,), cholesterol levels by , TG levels by , LDL levels by  and VLDL levels by , whereas there was no change with placebo. After one year the diff erence sustained between groups. Coronary events were rarely in the simvastatin group (,) than in the placebo group (). Coronary revascularizations were  in the placebo group and  in the simvastatin group. Rate of stroke was more often in the placebo group () than in the simvastatin group (,). So, reduction of acute CHD events is for , in the simvastatin group. Positive correlation was between CRP and CVD (r=,). Statin therapy reduced the risk of coronary hearth disease in diabetics without CHD.
Introduction
Diabetes mellitus type  is resulting from the interaction of obesity, infl ammation, and hyperglycaemia. Activated immunity and cytokine production lead to insulin resistance and other components of the metabolic syndrome, establishing the link between diabetes and atherosclerosis. Hyperglycaemia-induced endothelial dysfunction is mediated by increased oxidative stress, a promoter of adventitial infl ammation and vasa vasorum neovascularisation in experimental models of diabetic atherosclerosis. Recent studies have documented increased infl ammation, neovascularisation, and intraplaque haemorrhage in human diabetic atherosclerosis () . Th is inflammatory microangiopathic process is independently associated with plaque rupture, leading to coronary thrombosis. Tissue factor, the most potent trigger of the coagulation cascade, is increased in diabetic patients with poor glycemic control. Circulating tissue factor micro particles are also associated with apoptosis of plaque macrophages, closing the link among infl ammation, plaque rupture, and blood thrombogenicity. Highdensity lipoproteins, responsible for free cholesterol removal, are reduced in patients with insulin resistance and diabetes. High-density lipoprotein therapy leads to a signifi cant decrease in plaque macrophages and increase in smooth-muscle cells. Th ese benefi cial eff ects may be responsible for coronary plaque stabilization in patients treated with recombinant Apolipoprotein A-I Milano/ phospholipid complex. Finally, peroxisomal proliferators-activated receptors (PPARs) are now considered the nuclear transcriptional regulators of atherosclerosis. Three subfamilies, including PPAR-alpha, -delta, and -gamma, have been identifi ed with crucial roles in lipid metabolism, plaque infl ammation, expression of adhesion molecules and cytokines, and regulation of matrix metalloproteinase's. Multiple experimental studies have documented plaque stabilization with PPAR-gamma agonists, a group of medications holding great promise in the treatment of diabetes atherosclerosis. Elevated circulating infl ammatory markers such as C-reactive protein () and interleukin- predict the development of type  diabetes, and several drugs with anti-infl ammatory properties lower both acute-phase reactants and glycaemia (aspirin and thiazolidinediones) and possibly decrease the risk of developing type  diabetes (statin). Cardiovascular disease is the most important cause of morbidity and mortality in patients with type  diabetes. Statin therapy restores endothelial function in hyperlipidemic patients. Fluvastatin, simvastatin, lovastatin, atorvastatin, and cerivastatin, but not pravastatin, dose-dependently decrease smooth muscle cell (SMC) migration and proliferation. Moreover, statins are able to reduce cholesterol accumulation in macrophages in vitro by blocking cholesterol esterifi cation and endocytosis of modifi ed lipoproteins and matrix-degrading enzyme secretion () . In , the NCEP ATP III update recognized that not all patients with diabetes have a > -year risk for CHD; some patients with diabetes may have a moderate rather than a high risk for the disease () . Th e American Diabetes Association (ADA) guidelines recommend statin therapy in the majority of patients with diabetes () . Four large studies (which included a signifi cant number of patients with diabetes and no history of CHD) have aff ected treatment guidelines, despite various fl aws in their designs and some no signifi cant results () . While the authors of the Collaborative Atorvastatin Diabetes Study (CARDS) rationalized that statins are indicated for the primary prevention in the majority of patients with type  diabetes mellitus, they proposed that the debate should focus on determining if any patients with diabetes are at suffi ciently low risk to withhold statin therapy () . Th e authors of the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) suggested that a lower-risk primary prevention cohort would be expected to show less benefi t from statin therapy () .
We aimed to determine whether the administration of statins to type  diabetics without pre-existing coronary heart disease reduced the incidence of coronary heart disease and their eff ects on cholesterol and CRP levels.
Patients and Methods
All the participants were carefully interviewed, clinically examined, and laboratory tested to exclude conditions likely to provoke an infl ammatory response that was an exclusion criterion. Exclusion criteria: Serious heart, liver or kidney problems, history of renal transplant, recent history of drug or alcohol abuse, HbAc >, blood pressure higher than /mmHg, BMI > kg/m  , triglycerides >,mmol/dm  . In line with accepted guidelines, the LDL cholesterol level was used as a criterion for entry into the study. Ninety-fi ve obese patients with type  diabetes mellitus (mean age , years and mean BMI=, kg/m  , diabetes duration more than  years) without pre-existing coronary heart disease, were included in the analysis of data and were randomized to simvastatin (n=,  female and  male used  mg simvastatin daily) or placebo (n=,  female and  male) group (Table ) .
All the subjects were matched for age, sex, body mass index, blood pressure, and smoking habits. Laboratory measurements were checked every three months and that included serum levels of TC, TG, HDL-C, LDL-C, VLDL-C, plasma CRP level, HbAc and basal C-peptide. Vascular disease was considered to be present if there was evidence of angina, intermittent claudication, stroke, transient ischemic attack, and ECG abnormalities according to the Minnesota code. We evaluated incidence of acute coronary heart disease events, coronary revascularisation, or stroke in both group during one year period. Th e Centres for Disease Control and Prevention and AHA recommended using CRP as marker for primary prevention of major cardiovascular events. As proposal of that association, level of CRP classifi ed to three categories: ) <  mg/cm  = low risk; ) - mg/cm  = mild risk; ) >  mg/cm  high risk. Coronary screening clinics were established in Clinic for endocrinology, diabetes and metabolism diseases and in Heart Centre. Th e subjects were seen at every three-month intervals, and dietary advice was reinforced on each occasion. A fasting lipoprotein profi le and CRP was obtained every three months, and an ECG was recorded annually or as required clinically. All ECG results were verifi ed by visual inspection. All laboratory analyses were conducted at the Central Laboratory at the University of Sarajevo Clinics Centre. Student's T-test, percentile and correlation was performed in statistical analysis.
Results
In the beginning of study lipoproteins profi le and CRP level [, (Table ) .
Among  patients have total cholesterol > , mmol/ dm  . At  subjects the triglycerides concentrations were >, mmol/dm  , while at  HDL-cholesterol concentration was low. Mean HbAc was ,. Bad glucoregulation with HbAc >  was in more than  of subjects (p<,). On  diabetics HbAc was from , to ,, and on  HbAc was from , do ,. After six months simvastatin significantly lowered CRP levels by  ( Figure  ), (p<,), cholesterol levels by , TG levels by , LDL levels by  and VLDL levels by , whereas there was no change with placebo (Table  and Figure ) .
After one year the diff erence sustained between groups. At diabetics who have the highest level of CRP and fasting insulin cardiovascular diseases were frequently. Coronary events were rarer in the simvastatin group (n=; ,) than in the placebo group (n=; ) ( Figure  ).
Data are presented as mean ±SD. Coronary revascularizations were  () in the placebo group and  (,) in the simvastatin group (n=; ,). Rate of stroke were often in the placebo group (n=; ) than in the simvastatin group (n=; ,). So, reduction of acute coronary heart disease events is for , and rate of stroke for , in the simvaststin group. We found positive correlation between CRP and total cholesterol (r=,, P<,) and negative correlation between CRP and HDL levels (r=-,, P<,). CRP correlated signifi cantly with basal C-peptide (r=,) and with BMI (r=,). Positive correlation was between elevated CRP and CVD (r=,). We found a signifi cant interaction between the presence of diabetes and the eff ect of pre-treatment with statins on cardiovascular diseases.
Discussion
Th e study results showed reduction of acute coronary heart disease events for , and rate of stroke for , in the simvastatin group. Th e Heart Protection Study (HPS) results questioned the proposal that patients with diabetes and no history of CHD have the equivalent risk for a vascular event as those with pre-existing CHD () . In addition to signifi cantly reducing the risk of fi rst major vascular events by  in all patients and by  in patients with diabetes (both p<,), simvastatin  mg decreased the rate of all major vascular events (fi rst and subsequent) in these patients during the five-year follow-up. HPS investigators concluded that cholesterol lowering with statin therapy is generally effi cacious in patients with diabetes, including those without CHD and with relatively low LDL-C levels () . Th e results of the overall ASCOT-LLA (AngloScandinavian Cardiac Outcomes Trial Lipid-Lowering Arm) demonstrated a benefi t with atorvastatin therapy, but the type  diabetes mellitus subgroup did not demonstrate a signifi cant benefi t. While it is possible that a signifi cant benefi t in the primary endpoint could have occurred among patients with type  diabetes mellitus if the trial had continued for the full fi ve years, it cannot be concluded that a benefi t would have existed (). Th e Collaborative Atorvastatin Diabetes Study (CARDS), a double-blind randomised placebo-controlled trial, assessed primary prevention with atorvastatin mg daily in , patients with type  diabetes and at least one additional risk factor (smoking, microalbuminuria, retinopathy or hypertension) () . Participants were aged  years or above (mean age around  years) and had a serum LDL-C concentration of , mmol/dm  or lower;  were male. Th e LDL-C concentration was reduced more with atorvastatin (mean reduction , mmol/dm greater than with placebo,  CI ,-,, p<,). ASPEN, originally designed as a randomized, double-blind, placebo-controlled analysis that was conducted in a large patient population (n = ) with type  diabetes mellitus and a history of CHD, compared atorvastatin  mg daily with placebo () . Th e ASPEN results were not statistically signifi cant, demonstrating no signifi cant diff erence in primary and individual endpoints for all patients in either the primary or secondary prevention subgroup. In the primary prevention subgroup of patients, there was a no signifi cant reduction of fatal CHD plus nonfatal MI and stroke (fatal or nonfatal); however, there was a trend toward increased CV mortality risk. On the basis of these fi ndings, type  diabetes mellitus may not be considered a true risk equivalent to CHD. Th e Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) was a non-blinded randomised controlled trial designed to compare classes of antihypertensive drugs in patients aged  years or older with hypertension and at least one additional risk factor;  were male () . Pravastatin reduced LDL-C concentration by , mmol/dm more than placebo. Th e German Diabetes and Dialysis Study (D), a double-blind randomised placebo-controlled trial, assessed atorvastatin mg daily in , patients with type  diabetes and nephropathy requiring maintenance haemodialysis (a group at very high risk of developing cardiovascular disease) () . After a mean follow-up of around  years, atorvastatin had lowered the LDL cholesterol concentration (by a mean of around ,mmol/L more than with placebo), but not the likelihood of cardiovascular death, non-fatal coronary events or stroke (the primary endpoint:  with atorvastatin vs.  on placebo; p=,). Currently, ADA recommends that for people over the age of  years without overt CVD, statin therapy should be initiated to achieve an LDL-C reduction of - regardless of baseline LDL-C levels () . Th is treatment is prudent in diabetic patients with known CV risk factors or markedly increased LDL-C concentrations (≥ mg/cm), regardless of the presence of CVD; however, the question still remains as to whether statin therapy should be initiated in all patients with diabetes in the absence of other CV risk factors and an LDL-C concentration of < mg/cm. The National Institute for Health and Clinical Excellence (NICE) recommends statin therapy for primary prevention of cardiovascular disease in people with type  diabetes in whom, clinically, the cardiovascular disease risk has been estimated to be at least  over  years.
Th e cardiovascular diseases were often in aged diabetics. Th e mean age of patients was , years. Th e , of participants have high body weight. More than  of subjects have bad glucoregulation with HbAc >  (p<,). Among  patients have total cholesterol > , mmol/dm  . At  subjects the triglycerides concentrations were >, mmol/dm  , while at  HDL-C concentration was low. More than  subjects had CRP >  mg/cm  , which those classifi ed across AHA in category with high risk for atherosclerosis. CRP concentrations statistical signifi cantly correlated with coronary diseases (r=,; p<,), with HbAc (r=,), and with total cholesterol (r=,), as well. Results showed negative correlation between CRP and HDL-cholesterol (r =-,). Similar results showed moreover study () . Except cholesterol concentrations and CRP levels may helped to choice patients for statins treatment. Force/ Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), investigated relationship between LDL-cholesterol and CRP () . Th at explained as  patients with acute coronary syndrome in USA have normal LDL-cholesterol and high CRP. Therefore, CRP determination needs to be in the patients with middle coronary risk (- during  years).
Conclusion
Treatment with statins reduced the risk of coronary events in diabetics without CHD. Th e frequency of the need for coronary angiography and revascularization procedures was signifi cantly lower in the simvastatin group than in the placebo group. Except cholesterol concentrations and CRP levels may helped to choice patients for statins treatment. Elevated CRP in association with high insulin is a signifi cant cardiovascular risk in type  diabetics. CRP determination needs to be in the patients with middle coronary risk. 
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